中国肝、肾移植受者霉酚酸类药物应用专家共识(2023版)
Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients(2023 edition)
中华医学会器官移植学分会 中国医师协会器官移植医师分会 上海医药行业协会 薛武军 1吴建永 2陈刚 3王正昕 4陈志东5
作者信息
- 1. 西安交通大学第一附属医院肾脏病医院肾移植科,西安710061
- 2. 浙江大学医学院附属第一医院肾脏病中心,杭州310003
- 3. 华中科技大学同济医学院附属同济医院器官移植研究所,武汉430030
- 4. 复旦大学附属华山医院普外科,上海 200040
- 5. 上海交通大学医学院附属第六人民医院药剂科,上海 200233
- 折叠
摘要
为了提升临床医师对肝、肾移植受者霉酚酸类药物应用的认识,进一步规范霉酚酸类药物的临床应用,建立临床实践中不同霉酚酸类药物替换的基本原则,中华医学会器官移植学分会、中国医师协会器官移植医师分会和上海医药行业协会基于循证医学证据和临床实践经验形成此共识,希望能为肝、肾移植受者霉酚酸类药物的临床应用提供依据.
Abstract
To enhance clinical physicians'understanding of the use of mycophenolic acid in liver and kidney transplant recipients,further standardize the clinical use of mycophenolic acid,and establish basic principles for the switch of mycophenolic acids of different brands and formulations in clinical practice.This consensus,grounded in both evidence and clinical experience,has been collaboratively developed by the Branch of Organ Transplant of Chinese Medical Association,Branch of Organ Transplant Physicians of Chinese Medical Doctor Association,and the Shanghai Pharmaceutical Profession Association.The overarching hope is that this document will serve as a foundational reference for the clinical application of mycophenolic acids in liver and kidney transplant scenarios.
关键词
器官移植/肝移植/肾移植/霉酚酸类药物/吗替麦考酚酯/麦考酚钠Key words
Organ transplantation/Kidney transplantation/Liver transplantation/Mycophenolic acid/Mycophenolate mofetil/Mycophenolate sodium引用本文复制引用
出版年
2023
NETL
NSTL
万方数据